Howdy folks. It’s been a week since I last left you with a description of me in a somewhat compromising situation at St Barts.
Since then no one has been near my, you know, and although I have the tablet ready to purge the body (laxative) no date as yet.
Meanwhile in the research world there has been a breakthrough in the understanding of the specific conditions I have. (If science bores you, the last few of paragraphs should do you) 🙂
To summarise, scientists from the university of Southhampton presented their finds at an important conference in San Fransisco. Having been researching splenic marginal Zone lymphoma (the sub form of non Hodgkins lymphoma, that myself and some of my readers suffer from) they have (for full article I am quoting go to https://leukaemialymphomaresearch.org.uk/news-item/breakthrough-understanding-rare-lymphoma and my thanks to them for the information and to Sam Eggleton for pointing me to them)
‘used various sophisticated ‘gene sequencing’ techniques to screen DNA from 175 patients with (SMZL), a cancer of the immune system. They identified key genetic errors that can influence the speed at which the cancer develops in different patients.’
This is good news because A) by achieving breakthroughs of this nature it increases the understanding of the condition, which will hopefully lead to better treatments and prognosis. B) if research proves fruitful for a condition which is little known it encourages other teams to study it and for charities to fund other studies. C) because patients often develop immunities to a treatment when it has been used on them once it is important to keep up with new options and D) well, I have the condition so, you know, yay go team research.
It is important to note this study was funded by The blood cancer charity Leukaemia & Lymphoma Research. This shows raising money does yield results.
Trying to keep it simple it shows that
‘Errors in the TP53 gene in cancer cells were shown to be ‘drivers’ of the cancer, potentially acting as a warning for doctors of shorter survival times. The presence of faults in the KLF2 and NOTCH2 genes indicated that patients generally required intensive treatment for their disease more quickly.
Dr Matt Kaiser, Head of Research at Leukaemia & Lymphoma Research, said: “Understanding how different genetic changes contribute to a patients’ disease has allowed us to make huge strides in designing treatments for many different blood cancers, but until now splenic marginal zone lymphoma has been a bit behind. This research could help doctors and patients make more informed choices about treatment plans, and help to significantly improve the outlook for this group of patients.’
So now doctors know which genes, when faulty, cause faster progress they can start to find out ways to target these genomes and also give much more reliable prognosis.
It is worth noting that the disease tends to take two courses the more prevalent one being slower but a variant progressing much quicker. The condition usually changes to the quicker within the first two years (one year six months and counting), so being able to predict this is important for treatment options.
Anyway good news all around. Otherwise I am well, although my spleen is grumbling as it periodically does. I’m pretty content with life at the moment and with the new(ish) house and work being busy but rewarding I really shouldn’t complain.
Thank you all for your continued support, I really dont deserve the friends and family I have. Keep in touch and I’ll keep you posted. Enjoy the new year and make the most of the things you have! 🙂